PortViewPortView
Aspire Biopharma logo

Aspire Biopharma (ASBPW) Stock Analysis

NASDAQHealthcareBiotechnology

$0.02+0.00%
1-year price historyRange $0.01 – $0.08
52-week range$0.02
$0.02$0.04

What Aspire Biopharma does

Aspire Biopharma Holdings, Inc. operates as a biotechnology enterprise primarily focused on innovative diagnostic approaches and molecular analysis. The company's core mission involves engineering remarkably precise testing tools for the identification of various illnesses, utilizing breakthroughs in genetic and biochemical science to serve the needs of the healthcare and life science sectors.

Key metrics

Market cap
$172,528
Beta
0.15
Dividend yield
0.00%
Revenue / share
$0.09
50-day avg
$0.02
200-day avg
$0.02
52-week high
$0.04
52-week low
$0.02
CEO
Kraig T. Higginson

ETFs linked to ASBPW

Broad-market and Healthcare sector ETFs an investor holding Aspire Biopharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ASBPW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ASBPW in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Aspire Biopharma?
Aspire Biopharma trades under the ticker ASBPW on NASDAQ.
Which exchange is ASBPW listed on?
ASBPW is listed on NASDAQ.
What sector does Aspire Biopharma operate in?
Aspire Biopharma is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze ASBPW in a portfolio?
PortView shows ASBPW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.